Sun Pharmaceutical Industries, an international, integrated, speciality pharmaceutical company, witnessed a rise in share price on Tuesday after it has completed acquisition of GlaxoSmithKline's (GSK) opiates business which was announced in March 2015. The company today begins integration of its Australian opiates business.

The company said, "This acquisition fortifies Sun Pharma's global position with two Opiates manufacturing facilities in Port Fairy & Latrobe (both in Australia) complementing its current API manufacturing footprint globally."

Anil Kumar Jain, CEO, API Business, Sun Pharma said, "The successful completion of this acquisition enables us to leverage our unique position in the global opiates business by capitalizing our global footprint and global ranking in the specialty generics market. Sun Pharma stays committed to uncompromised product quality, 100% compliance and innovation."

Shares of Sun Pharmaceutical Industries are trading at Rs 903.50, up Rs 5.8, or 0.65% at the Bombay Stock Exchange (BSE) on Tuesday at 12:28 p.m.

The scrip has touched an intra-day high of Rs 915.30 and low of Rs 883.40. The total volume of shares traded at the BSE is 162,717.